Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
antisense oligonucleotide targeting NFIC
- Development stage
- Preclinical
- Lead developer
- Fudan University
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Antisense oligonucleotide targeting NFIC is an investigational antisense oligonucleotide (ASO) designed to knock down nuclear factor I C (NFIC). Developed by researchers at Wuhan University and Fudan University, this therapeutic candidate targets the male-enriched transcription factor NFIC, which binds to hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) and recruits the histone acetyltransferase p300 to drive male-biased HBV transcription. In preclinical models, antisense-mediated depletion of NFIC robustly suppressed viral transcription in vivo without detectable toxicity, highlighting its potential as a host-directed therapy for chronic hepatitis B.
- Other names
- NFIC ASONFIC antisense oligonucleotide
02
Targets
NFIC (Nuclear factor 1 C-type)
Beyond the preview
Go deeper on antisense oligonucleotide targeting NFIC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on antisense oligonucleotide targeting NFIC.